Top picks: CDH, LPC, ALKEM, DISH and GRAN Post the bumper domestic sector numbers in 2QFY18 which provided a temporary boost to the pharma pack, we believe that 3QFY18E is likely to be more of a mixed bag. Companies with limited competition launches in the US such as CDH, CIPLA, ARBP and STR are likely to report strong numbers in 3QFY18E. Domestic focused companies like ALKEM and TRP are likely to benefit to some extent from the low base of 3QFY17 which was impacted by demonetisation and the trailing effects of channel re-stocking. However, sequential growth looks difficult. Overall, we see 1.4% YoY growth for our coverage universe and the EBITDA margin to remain steady sequentially at 21.9% in 3QFY18E.